The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism

Drugs

Volumn 69, Issue 5, 2009, Pages 535-548

  Malone, Richard P ^a   Waheed, Ayesha ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; LIPID; MESORIDAZINE; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

AGGRESSION; AGRANULOCYTOSIS; AKATHISIA; ANGER; AUTISM; AUTOMUTILATION; BEHAVIOR; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FATIGUE; HUMAN; HYPERACTIVITY; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOKINESIA; IMPULSIVENESS; INCREASED APPETITE; INTERPERSONAL COMMUNICATION; IRRITABILITY; LANGUAGE; MONITORING; PRESCRIPTION; PROLACTIN BLOOD LEVEL; PSYCHOSOCIAL WITHDRAWAL; QT PROLONGATION; REVIEW; RISK; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL INTERACTION; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; DYSKINESIA, DRUG-INDUCED; HUMANS;

EID: 64949086422     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969050-00003     Document Type: Review

References (59)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
2. Newschaffer Cf, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2006; 28: 21.1-21.24
3. Center for Disease Control. Prevlence of autism spectrum disorders: Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. MMWR (Surveillance Summaries) 2007; 56 (SS-1): 12-28
4. Malone RP, Gratz S, Delaney MA, et al. Recent advances in drug treatments in children and adolescents with pervasive developmental disorder. CNS Drugs 2005; 19 (11): 923-34
5. Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 2005; 19 (5): 533-50
6. Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry 1978; 17 (4): 640-55
7. Cohen IL, Campbell M, Posner D, et al. Behavioral effects of haloperidol in young autistic children. J Am Acad Child Adolesc Psychiatry 1980; 19 (4): 665-77
8. Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141 (10): 1195-202
9. Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19 (2): 227-39
10. Perry R, Campbell M, Adams P, et al. Long term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28 (1): 87-92
11. Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry 1970; 126 (11): 1670-3
12. Naruse H, Nagahata M, Nakane Y, et al. A multi-center double blind trial of pimozide, haloperidol, and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 1982; 48 (4): 173-84
13. Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21 (4): 440-44
14. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: 634-41
15. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16 (5): 541-8
16. Ernst M, Magee HG, Gonzalez NM, et al. Pimozide in autistic children. Psychopharmacol Bull 1992; 28 (2): 187-91
17. Tarjan G, Lowery VE, Wright SW. Use of chlorpromazine in two hundred seventy eight mentally deficient patients. AMA J Dis Child 1957; 94 (3): 294-300
18. Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36 (6): 835-43
19. Fish B, Shapiro T, Campbell M. Long term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine. Am J Psychiatry 1966; 123: 32-9
20. Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). Risperidone in children with autism for serious behavioral problems. N Engl J Med 2002; 347: 314-21
21. Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. Am J Psychiatry 2005; 162 (7): 1361-9
22. Troost PW, Lahuis BE, Steenhuis M, et al. Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adol Psychiatry 2005; 44 (11): 1137-44
23. Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short and long term safety and effectiveness. J Am Acad Child Adol Psychiatry 2002; 41 (2): 140-7
24. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adol Psychiatry 2001; 40 (8): 887-94
25. National Institute of Mental Health (NIMH). Long-term olanzapine treatment in children with autism [Clinical-Trials.gov identifier NCT00183404]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 25]
26. Reilly T, Kirk M. Atypical antipsychotics and newer anti-depressants. Emerg Med Clin North Am 2007; 25 (2): 477-97
27. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004; 4 (2): 179-86
28. FDA. FDA background on Zeldox™ (ziprasidone hydro-chloride capsules) [online]. Available from URL: http:// www.fda.gov/ohrms/dockets/ac/00/ backgrd/3619blb.pdf [Accessed 2009 Feb 11]
29. Moss AL Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72: 23-5B
30. Harrigan E, Miceli J, Anzizno A, et al. A randomized evaluation of the effects of six antipsychotic agents on the QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharm 2004; 24 (1): 62-9
31. Blair J, Scahill L, State M, et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005; 44 (1): 73-9
32. Loebel A, Miceli J, Chappell P, et al. Electrocardiographic changes with ziprasidone [letter]. J Am Acad Child Adolesc Psychiatry 2006; 45 (6): 636-7
33. Malone RP, Delaney MA, Cater JR, et al. Ziprasidone in adolescents with autism: an open pilot study. J Child Adolesc Psychopharm 2007; 17 (6): 779-90
34. McDougle CJ, Kem DL, Posey DL Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41 (8): 921-7
35. Kane J, Carson W, Saha A, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-71
36. Potkin S, Saha A, Kujawa M, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90
37. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behaviors in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14 (3): 455-63
38. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006; 16 (5): 549-60
39. Owen R, Findling RL, Carlson G, et al. Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6 - 17 years old): results from a double-blind, randomized, placebo-controlled trial (Study CN 138-178). Poster presentation at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry 2008 Oct 28-Nov 2; Chicago (IL)
40. Owen R, Marcus R, Aman MG, et al. Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6-17 years old): results from a fixed-dose, double-blind, randomized, placebo-controlled trial (Study CN 138-179). Poster presentation at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry 2008 Oct 28-Nov 2; Chicago (IL)
41. Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996; 153:738
42. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14 (2): 287-94
43. Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9 (2): 99-107
44. Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004; 65 (11): 1531-6
45. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16: 575-87
46. Laita P, Cifuentes A, Doll A, et al. Antipsyhotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17: 487-501
47. Hellings JA, Zarcone JR, Crandall K, et al. Weight gained in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11: 229-38
48. Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Pyschiatry 2003; 64: 1039-47
49. Hellings JA, Zarcone JR, Reese RM, et al. Crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord 2006; 36: 401-11
50. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 2004; 39: 486-7
51. Malone RP. Stereotypies and neuroleptic-related dyskinesias in children with autism. in: richardson ma, haughland g, editors. use of Neuroleptics in Children. Washington, DC: American Psychiatric Press, 1995: 121-36
52. Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999; 50 (2): 171-4
53. Lee PE, Sykora K, Sudeep SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005; 53: 1374-9
54. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation anti-psychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161 (3): 414-25
55. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005; 50 (11): 703-14
56. Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001; 62 (12): 967-74
57. Brixner DL, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006; 40: 626-32
58. Hellings JA, Zarcone JR, Valdovinos MG, et al. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15 (6): 885-92
59. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocri-nologists; and the North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004; 65 (2): 267-72